Literature DB >> 2242067

Dermal mast cell degranulation in systemic sclerosis.

J R Seibold1, R C Giorno, H N Claman.   

Abstract

Paired biopsy samples from involved and uninvolved skin were obtained from 19 patients with generalized scleroderma (11 with early, progressive disease and 8 with late, improving disease). Skin biopsy samples were double stained for mast cell granules and for mast cell membrane. The number of mast cells was increased in patients with systemic sclerosis (SSc), in both involved and uninvolved skin and in both early and late disease. There was an increase in the number of degranulated mast cells in the involved skin of patients with both early and late disease and in the not-yet-involved skin of patients with early disease; however, there was no increase in the number of degranulated mast cells in areas of previously involved but now normal skin of patients with late disease. Increases in mast cell number and degranulation precede clinically apparent dermal fibrosis in SSc. These observations and the absence of mast cell degranulation in regressing skin suggest a participatory role of the mast cell in the clinical progression of skin changes in SSc.

Entities:  

Mesh:

Year:  1990        PMID: 2242067     DOI: 10.1002/art.1780331114

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Animal models for scleroderma: an update.

Authors:  Yan Zhang; Anita C Gilliam
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

4.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice.

Authors:  Naotaka Shiota; Eiichi Kakizoe; Keiko Shimoura; Tetsuya Tanaka; Hideki Okunishi
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

6.  Mast Cell Stabilization Ameliorates Autoimmune Anti-Myeloperoxidase Glomerulonephritis.

Authors:  Poh-Yi Gan; Kim M O'Sullivan; Joshua D Ooi; Maliha A Alikhan; Dragana Odobasic; Shaun A Summers; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

7.  Immunological modulation of human cardiac mast cells.

Authors:  G Marone; G de Crescenzo; G Florio; F Granata; V Dente; A Genovese
Journal:  Neurochem Res       Date:  1999-09       Impact factor: 3.996

8.  Mast cell immunohistochemistry: non-immunological immunostaining mediated by non-specific F(ab')2-mast cell secretory granule interaction.

Authors:  P M Schiltz; J Lieber; R C Giorno; H N Claman
Journal:  Histochem J       Date:  1993-09

Review 9.  Mast cells and immunological skin diseases.

Authors:  Daniel Navi; Jun Saegusa; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

10.  Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts.

Authors:  A Nagler; V Segal; S Slavin; F Levi-Schaffer
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.